Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis

Affiliations

• ¹ Department of Pediatric Neurology, Catholic University, Rome, Italy. eugeniomaria.mercuri@unicatt.it.
• ² Centro Clinico Nemo, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy. eugeniomaria.mercuri@unicatt.it.
• ³ Neuromuscular Unit, Department of Neurology and Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu, Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.
• ⁴ UCL Great Ormond Street Institute of Child Health, London, UK.
• ⁵ National Institute for Health Research, Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London, London, UK.
• ⁶ Parent Project APS, Rome, Italy.
• ⁷ Hôpital Necker-Enfants Malades, Paris, France.
• ⁸ Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
• ⁹ Department of Pediatrics, Gothenburg University, Queen Silvia Children's Hospital, Gothenburg, Sweden.
• ¹⁰ Department of Neurology, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
• ¹¹ Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS), Pittsburgh, PA, USA.
• ¹² Center for Genetic Medicine, Children's National Health System and the George Washington, Washington, DC, USA.
• ¹³ PTC Therapeutics Inc., South Plainfield, NJ, USA.
• ¹⁴ PTC Therapeutics Germany GmbH, Frankfurt, Germany.
• ¹⁵ University of California Davis School of Medicine, Davis, CA, USA.